Biosimilar Interchangeability: Limited Exclusivity Should Mean Limited Testing – GPhA
This article was originally published in The Pink Sheet Daily
Executive Summary
Although AbbVie is petitioning FDA for expansive definition of 'any given patient' requirement, GPhA and its Biosimilars Council argue that Congress knew how to write the statute more broadly, but didn't.
You may also be interested in...
Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity
The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.
Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity
The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.
Real-World Evidence Will Take Center Stage At US FDA Advisory Committee On COVID Boosters
If regulators agree with Pfizer’s conclusions – and briefing documents suggest that’s a big if – about real-world studies showing Comirnaty’s effectiveness waning over time, thereby justifying the need for a booster dose, it could be part of a historical moment for FDA’s use of RWE.